CN105853917A - Pharmaceutical composition for treating chronic pharyngitis and preparation method and application thereof - Google Patents
Pharmaceutical composition for treating chronic pharyngitis and preparation method and application thereof Download PDFInfo
- Publication number
- CN105853917A CN105853917A CN201610286872.8A CN201610286872A CN105853917A CN 105853917 A CN105853917 A CN 105853917A CN 201610286872 A CN201610286872 A CN 201610286872A CN 105853917 A CN105853917 A CN 105853917A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- chronic pharyngitis
- treatment
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The invention discloses a pharmaceutical composition for treating chronic pharyngitis and a preparation method and application thereof. The composition is prepared from active ingredients mainly comprising, by weight, 10-20 parts of radix astragali, 10-20 parts of prepared glossy privet fruits, 6-18 parts of rhizoma atractylodis macrocephalae, 6-18 parts of poria cocos, 6-18 parts of radix curcumae, 4-8 parts of sun euphorbia herb and 2-4 parts of semen oroxyli. The pharmaceutical composition has the functions of nourishing yin and tonifying qi and regenerating body fluid and moistening dryness, and is used for treating chronic pharyngitis. The pharmaceutical composition is convenient to take, stable in function, define in curative effect, stable in dosage form, controllable in quality, free of toxic and side effect and capable of meeting the needs of patients.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to the medicine of a kind for the treatment of chronic pharyngitis made with Chinese medicine as raw material
Compositions and its preparation method and application.
Background technology
Chronic pharyngitis is under pharyngeal mucosa, mucosa and adenoid diffusivity inflammation, is often the one of upper respiratory tract chronic inflammatory disease
Part, is common clinical, frequently-occurring disease.This disease course of disease is long, and more, the most otorhinolaryngologic difficult problem, the most also to patient for touching difficulty
Bring the biggest misery.Along with the development of industry, air, severe water pollution, add bad living habit and indiscriminate
By reasons such as antibiotic, respiratory system disease is caused to grow with each passing day, especially higher with chronic pharyngitis sickness rate, its morbidity according to statistics
Rate urban population accounts for the 10%～20% of disease of pharynx, and rural population accounts for 5.5%, and presents ascendant trend year by year.
Doctor trained in Western medicine dispels the cause of disease to using the treatment of chronic pharyngitis more, gives up tobacco and wine, it is to avoid dust and harmful gas etc., for oral administration main
Iodine preparation to be used.The uncertain therapeutic efficacy of Western medicine is cut, although using inustion that foreign body in pharynx sense is made moderate progress, but glutinous because destroying
The reasons such as the glandular secretion of film and scar contracture, often bring dry pharynx, pharyngalgia to increase the weight of, and Chinese traditional treatment chronic pharyngitis is than west
Doctor has its unique curative effect.
Summary of the invention
It is an object of the invention to provide the pharmaceutical composition of a kind for the treatment of chronic pharyngitis made with Chinese medicine as raw material.
It is a further object of the present invention to provide the extract of a kind of aforementioned pharmaceutical compositions, preparation method and applications.
The purpose of the present invention can be reached by following measures:
A kind of pharmaceutical composition treating chronic pharyngitis, its active component is mainly made up of the crude drug of following weight portion: yellow
Stilbene 10-20 part, Fructus Ligustri Lucidi Preparata 10-20 part, Rhizoma Atractylodis Macrocephalae 6-18 part, Poria 6-18 part, Radix Curcumae 6-18 part, Herba Euphorbiae Helioscopiae 4-8 part,
Semen Oroxyli 2-4 part.
The active component of pharmaceutical composition of the present invention can be only made up of above-mentioned each crude drug, it is also possible in this combination further
Add other raw material of Chinese medicine medicines or Western medicine to improve the effect of this pharmaceutical composition or to obtain other effects further.
In a kind of preferred version, the active component of this pharmaceutical composition is primarily or entirely by the crude drug system of following weight portion
Become: Radix Astragali 12-18 part, Fructus Ligustri Lucidi Preparata 12-18 part, Rhizoma Atractylodis Macrocephalae 8-16 part, Poria 8-16 part, Radix Curcumae 8-16 part, Herba Euphorbiae Helioscopiae
5-7 part, Semen Oroxyli 2-4 part.
In a kind of preferred version, the active component of this pharmaceutical composition is primarily or entirely by the crude drug system of following weight portion
Become: the Radix Astragali 15 parts, Fructus Ligustri Lucidi Preparata 15 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, 12 parts of Poria, Radix Curcumae 12 parts, Herba Euphorbiae Helioscopiae 6 parts, wood butterfly
Butterfly 3 parts.
In the pharmaceutical composition of the present invention, the weight portion of each crude drug can arbitrarily adjust in the range of being provided or select
Select, to adapt to the requirement of different situations.Such as in the case of the weight portion at other crude drug adjusts or be unregulated, the Radix Astragali can
With 10,11,12,13,14,15,16,17,18,19,20 parts or more aliquot (10.5,11.5,12.5,
13.5,17.5,18.5,19.5 etc.) proportioning arbitrarily selects；Similar, Fructus Ligustri Lucidi Preparata can also 10,11,12,
13,14,15,16,17,18,19,20 parts or more aliquot (10.5,11.5,12.5,13.5,17.5,18.5,
19.5 etc.) proportioning arbitrarily selects；The Rhizoma Atractylodis Macrocephalae can also 6,7,8,9,10,11,12,13,14,15,16,
17, the proportioning of 18 parts or more aliquot (10.5,11.5,12.5,13.5,17.5 etc.) arbitrarily selects；Poria also may be used
With 6,7,8,9,10,11,12,13,14,15,16,17,18 parts or more aliquot (10.5,11.5,
12.5,13.5,17.5 etc.) proportioning arbitrarily selects；Radix Curcumae can also 6,7,8,9,10,11,12,13,
14, the proportioning of 15,16,17,18 parts or more aliquot (10.5,11.5,12.5,13.5,17.5 etc.) is arbitrarily selected
Select；Herba Euphorbiae Helioscopiae can also in the proportioning of 4,5,6,7,8 parts or more aliquot (4.5,5.5,6.5,7.5 etc.) arbitrarily
Select；Semen Oroxyli can also be in the proportioning of 2,2.5,3,3.5,4 parts or more aliquot (2.1,2.8,3.1,3.6 etc.)
In arbitrarily select.
The Rhizoma Atractylodis Macrocephalae in the present invention uses the Rhizoma Atractylodis Macrocephalae (stir-fry), i.e. through the preliminary Rhizoma Atractylodis Macrocephalae (parched) concocted.
Crude drug in the pharmaceutical composition of the treatment chronic pharyngitis of the present invention is extracted rear or direct with pharmaceutically acceptable
Adjuvant makes oral formulations, injection or external preparation, further, it can make oral liquid, capsule, tablet,
The pharmaceutically acceptable dosage forms such as granule, pill, pellet, soft capsule, drop pill, dispersible tablet, effervescent tablet, chewable tablet.
In corresponding preparation, pharmaceutically acceptable adjuvant can include but not limited to dextrin, lactose, starch, sucrose, Portugal
Grape sugar, microcrystalline Cellulose, magnesium stearate, mannose, methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose, sweet
One or more of oil and steviosin.
The invention provides a kind of drug extract treating chronic pharyngitis, it is that above-mentioned pharmaceutical composition is through Extraction solvent
The extracting solution extracted and obtain or extractum；Described Extraction solvent is selected from water or alcohol, such as ethanol etc..
The invention provides the preparation method of the pharmaceutical composition of a kind of above-mentioned treatment chronic pharyngitis, each crude drug respectively or is mixed
Extract together after conjunction and obtain extract, after then mixing with adjuvant, make acceptable preparation formulation on pharmaceutics.
The preparation method of a kind of pharmaceutical composition treating chronic pharyngitis, it comprises the steps: that (1) takes the Radix Astragali, Fructus Ligustri Lucidi processed
Son, the Rhizoma Atractylodis Macrocephalae, Poria, Radix Curcumae, Herba Euphorbiae Helioscopiae and Semen Oroxyli, boiling, merge decoction liquor, filter, filtrate concentrates, precipitate with ethanol,
Stand, receive cream, dry, pulverize into extract powder；(2) take above-mentioned extract powder interpolation adjuvant and make acceptable system on pharmaceutics
Agent dosage form.
The method that the invention provides the pharmaceutical composition of a kind of concrete treatment chronic pharyngitis, it comprises the steps:
1) take the Radix Astragali, Fructus Ligustri Lucidi Preparata, the Rhizoma Atractylodis Macrocephalae (stir-fry), Poria, Radix Curcumae, Herba Euphorbiae Helioscopiae, Semen Oroxyli decoction pieces, add envelope-bulk to weight ratio
For 6-10 times amount water (ml/g, lower same), decoct 1-3 time, each 1-2h, merge decoction liquor；
2) decoction liquor filters, and filtrate is concentrated into relative density 1.10-1.20；
3) precipitate with ethanol, alcohol content is 50-70%, standing, and time of repose is 12-48h
4) being concentrated into relative density during alcohol deposit fluid 50 DEG C-70 DEG C is 1.20-1.25, is dried, obtains dry extract；
5) above-mentioned dry extract is pulverized, sieve, extract powder must be become；
6) above-mentioned extract powder interpolation adjuvant is made oral liquid, capsule, tablet, granule, pill, pellet, soft
Capsule, drop pill, dispersible tablet, effervescent tablet, chewable tablet.
The pharmaceutical composition of the treatment chronic pharyngitis of the present invention can be applicable in preparation treatment chronic pharyngitis medicine.
The beneficial effect comprise that
1. the present invention is formed by 7 taste Chinese medicine compound, including having the Radix Astragali of qi invigorating functions, and the female of effect of strengthening the body resistance antiinflammatory
Loyal son, invigorating the spleen and benefiting QI, the Rhizoma Atractylodis Macrocephalae (stir-fry) of effect of dampness diuretic, the Radix Curcumae of promoting the circulation of QI to relieve pain effect, the Fu of the effect of damp eliminating diuretic
Siberian cocklebur, the Semen Oroxyli of removing heat from the lung and relieving sorethroat effect, and inducing diuresis to remove edema, the Herba Euphorbiae Helioscopiae of the detoxicating functions that reduces phlegm.
2. Chinese medicine is mostly decoction at present, and recipe quantity is big, flavour of a drug are many, uses inconvenience, and the present invention is only by seven flavor medicine, drug effect
Learn experiment and prove that there is obvious Replenishing QI and nourishing YIN, the effect moisturized of promoting the production of body fluid.
3. preparation technology is simple, and flavour of a drug are few, cost-effective, and medicine of the present invention can be made into the agent such as granule, capsule, tablet
Type, patient's taking convenience.
4. the present invention shows have Replenishing QI and nourishing YIN, the effect moisturized of promoting the production of body fluid through the pharmacological results, develops into treatment chronic pharyngitis
New drug, its market capacity is big, and economic benefit and social benefit are obvious, has preferable application valency in terms for the treatment of chronic pharyngitis
Value.
Detailed description of the invention
Form by the following examples, is described in further detail the foregoing of the present invention again, but should this not managed
The scope for the above-mentioned theme of the present invention that solves is only limitted to Examples below, and all technology realized based on foregoing of the present invention all belong to
In the scope of the present invention.
Weight proportion listed by the equal according to the form below of following example weighs needed raw material of the present invention, unit: part
Chinese crude drug of the present invention is Chinese Pharmacopoeia standard in addition to Herba Euphorbiae Helioscopiae.
Example of formulations
Embodiment 1:
The Radix Astragali 10 parts, Fructus Ligustri Lucidi Preparata 20 parts, the Rhizoma Atractylodis Macrocephalae (stir-fry) 6 parts, 18 parts of Poria, Radix Curcumae 6 parts, Herba Euphorbiae Helioscopiae 8 parts, wood
Butterfly 2 parts.Adding envelope-bulk to weight ratio is 6-10 times amount water, decocts 3 times, each 1-2h, merges decoction liquor；Decoction liquor is filtered
Crossing, filtrate is concentrated into relative density 1.10-1.20；Precipitate with ethanol, alcohol content is 50-70%, standing, and time of repose is 12-48h；
Being concentrated into relative density during alcohol deposit fluid 50 DEG C-70 DEG C is 1.20-1.25, is dried, obtains dry extract；Above-mentioned dry extract is pulverized,
Sieve, extract powder must be become；Above-mentioned extract powder is added dextrin or lactose or starch or magnesium stearate and steviosin, mixing, system
Grain, tabletting, i.e. make tablet.
Embodiment 2:
The Radix Astragali 15 parts, Fructus Ligustri Lucidi Preparata 15 parts, the Rhizoma Atractylodis Macrocephalae (stir-fry) 12 parts, 12 parts of Poria, Radix Curcumae 12 parts, Herba Euphorbiae Helioscopiae 6 parts,
Semen Oroxyli 3 parts.Adding envelope-bulk to weight ratio is 6-10 times amount water, decocts 3 times, each 1-2h, merges decoction liquor；Decoction liquor
Filtering, filtrate is concentrated into relative density 1.10-1.20；Precipitate with ethanol, alcohol content is 50-70%, standing, and time of repose is 12-48h；
Being concentrated into relative density during alcohol deposit fluid 50 DEG C-70 DEG C is 1.20-1.25, is dried, obtains dry extract；Above-mentioned dry extract is pulverized,
Sieve, extract powder must be become；Above-mentioned extract powder is added dextrin or lactose or starch or microcrystalline Cellulose and steviosin, mixes,
Pelletize, i.e. make granule.
Embodiment 3:
The Radix Astragali 20 parts, Fructus Ligustri Lucidi Preparata 10 parts, the Rhizoma Atractylodis Macrocephalae (stir-fry) 18 parts, 6 parts of Poria, Radix Curcumae 18 parts, Herba Euphorbiae Helioscopiae 4 parts, wood
Butterfly 6 parts.Adding envelope-bulk to weight ratio is 6-10 times amount water, decocts 1-3 time, each 1-2h, merges decoction liquor；Decoction liquor
Filtering, filtrate is concentrated into relative density 1.10-1.20；Precipitate with ethanol, alcohol content is 50-70%, standing, and time of repose is 12-48h；
Being concentrated into relative density during alcohol deposit fluid 50 DEG C-70 DEG C is 1.20-1.25, is dried, obtains dry extract；Above-mentioned dry extract is pulverized,
Sieve, extract powder must be become；Above-mentioned extract powder is added dextrin or lactose or starch and steviosin, mixing, pelletizes, be distributed into
Capsule, i.e. makes capsule.
Pharmacodynamics test
In embodiment 4-7, the medicine of each dosage group specifically uses embodiment 2 to prepare gained.
Embodiment 4: the impact on mice dimethylbenzene proinflammatory effect
(1) method: select male ICR mouse about body weight 20g, be randomly divided into 5 groups, Normal group, positive group,
Low dose group (5.625/kg), middle dosage group (11.25g/kg)；High dose group (22.5g/kg).By the two of 0.03ml
Toluene is applied to two sides before and after the auris dextra exterior feature of every mice, and left ear, as comparison, causes 1h after inflammation, under etherization puts to death
Animal, takes off the auricle of left-right ear same area, weighs with the card punch of 9mm diameter, calculates swelling and suppression ratio,
Swelling=auris dextra sheet weight-left auricle weight；Suppression ratio (%)=(blank group ear swelling degree-administration group ear swelling degree)
/ blank group ear swelling degree × 100%.
(2) result
The impact rather formed mice ear swallowed slowly by watch 1
Note: compared with model group: * P < 0.05, * * P < 0.01
(3) conclusion: this medicine gets final product the formation of significance suppression mice ear in 5.625g/kg (* p < 0.05).It presses down
Effect processed is suitable with the inhibition (* p < 0.05) of the dexamethasone acetate of 0.45mg/kg.
Embodiment: 5: the impact (hot plate method) on mice analgesic activity
(1) method: select male ICR mouse about body weight 20g, be randomly divided into 5 groups, Normal group, positive group,
Low dose group (5.625/kg), middle dosage group (11.25g/kg)；High dose group (22.5g/kg).Successive administration 7 days,
Lumbar injection aspirin (0.15ml/10g), medicine gastric infusion (1.5ml/100g) of the present invention.After being administered at the 7th day
15,30,45,60min respectively surveys the pain sensation and reacts 1 time.In testing, such as analgesia reaction in 60 seconds, should take out immediately,
And in terms of 60 seconds.Record pain thresholding, observes the performance before and after two Mus are administered, and carefully records observed result.
(2) result: use hot plate method that invention formulation effect is evaluated, either invention formulation or positive drug
Aspirin is administered the pain territory the most not significantly improving mice for latter 15 minutes compared with blank group, is administered latter 30 minutes high doses
Group can improve the pain territory of mice with significance, and its analgesic effect is suitable with positive drug aspirin.The onset time of middle dosage group
Will be by 45 minutes, high dose group analgesic activity now has weakened, and aspirin still keeps effect of significantly easing pain
Really.Time between when administered by 60 minutes, only high dose group has significant analgesic activity.
(3) conclusion: the invention formulation analgesic activity that 45 minutes have significance after 11.25g/kg dosed administration
(P* < 0.5), latter 30 minutes (P*** < 0.001) of 22.5g/kg analgesic activity onset and administration, the analgesia with aspirin is made
With comparing, the analgesic activity persistent period is long, is administered latter 60 minutes and still has significance analgesic activity (P* < 0.5).
Embodiment 6: the impact on rat saliva secretion
(1) method: select body weight 180g-220g rat 48, be randomly divided into 6 groups, often group 8, is male.
Gastric infusion (1ml/100g), once a day, successive administration 6d, 12h fasting before test, can't help water, be administered in last
Rear 30min, gavage gives atropine (0.16mg/kg), after giving atropine 20min, lumbar injection chloral hydrate (10%,
0.35mL/100g), and start to measure the salivation amount of rat.Method: fixed by rat, with mosquito forceps by similar weight
Dry cotton ball (50 ± 5) mg put people rat Sublingual, measure the salivation amount of rat, every every 30min of cotton balls changes 1 time,
METHOD FOR CONTINUOUS DETERMINATION 120min, calculates maximum salivation amount by the weight difference of dry cotton ball before and after weighing.
(2) result: medicine 15g/kg gets final product significance and promotes the salivation (* P < 0.05) of rat xerostomia model, works as agent
It is that it promotes that (* * P < 0.01) is increased in salivation effect that amount reaches 30g/kg.
The impact (x ± sd, n=8) that rat saliva is secreted by table 2
(3) conclusion: invention formulation promotes rat xerostomia model salivation at the equal significance of 15g/kg, 30g/kg, its
Facilitation is slightly below the atropinic facilitation of positive drug.
Embodiment 7: the impact of excretion phenol red on mouse salivary
(1) method: select male ICR mouse about body weight 20g, be randomly divided into 5 groups, respectively blank group,
Positive (mucosolvan) group, low dose group (3.75g/kg), middle dosage group (7.5g/kg)；High dose group (15g/kg), often
Organize 10.Gastric infusion, once a day, is administered volume 20mL/kg, successive administration 8d, 30min after last administration,
Lumbar injection 2.5% phenol red normal saline solution 0.1ml/10g.Put to death animal, fixing Mus body after injection 30min, separate
Trachea, tracheal intubation is also connected with syringe, uses 5%NaHCO3 1mL, be slowly injected into tracheal strips, inhale the most gently
Go out, 3 times the most repeatedly, merge 3 irrigating solutions and place certain times and make contamination precipitation, the transparent red supernatant obtained,
By spectrophotometer wavelength 545nm colorimetric, calculate phenol red amount according to phenol red standard curve.
(2) result:
The impact of table 3 excretion phenol red on mice (N=10)
Note: compared with matched group,*P<0.05；***P<0.01。
(3) conclusion: invention formulation starts just to promote the phenol red excretion of mice by significance from 11.25g/kg dosage
(* P < 0.05), the promotion excretion of high dose is more significantly (* * * P < 0.01), with positive drug mucosolvan 18.2mg/kg's
It is suitable that decorporation lets out efficiency.
Claims (10)
1. the pharmaceutical composition treating chronic pharyngitis, it is characterised in that its active component is mainly by the raw material of following weight portion
Medicine is made: Radix Astragali 10-20 part, Fructus Ligustri Lucidi Preparata 10-20 part, Rhizoma Atractylodis Macrocephalae 6-18 part, Poria 6-18 part, Radix Curcumae 6-18
Part, Herba Euphorbiae Helioscopiae 4-8 part, Semen Oroxyli 2-4 part.
The pharmaceutical composition for the treatment of chronic pharyngitis the most according to claim 1, it is characterised in that its active component mainly by
The crude drug of following weight portion is made: Radix Astragali 12-18 part, Fructus Ligustri Lucidi Preparata 12-18 part, Rhizoma Atractylodis Macrocephalae 8-16 part, Poria 8-16
Part, Radix Curcumae 8-16 part, Herba Euphorbiae Helioscopiae 5-7 part, Semen Oroxyli 2-4 part.
The pharmaceutical composition for the treatment of chronic pharyngitis the most according to claim 2, it is characterised in that its active component is by following
The crude drug of weight portion is made: the Radix Astragali 15 parts, Fructus Ligustri Lucidi Preparata 15 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, 12 parts of Poria, Radix Curcumae 12
Part, Herba Euphorbiae Helioscopiae 6 parts, Semen Oroxyli 3 parts.
The pharmaceutical composition for the treatment of chronic pharyngitis the most according to claim 1, it is characterised in that the crude drug in said composition
Oral formulations, injection or external preparation is made after extracted or directly with pharmaceutically acceptable adjuvant.
The pharmaceutical composition for the treatment of chronic pharyngitis the most according to claim 4, it is characterised in that the crude drug in said composition
After extracted or directly with pharmaceutically acceptable adjuvant make oral liquid, capsule, tablet, granule, pill,
Pellet, soft capsule or drop pill.
The pharmaceutical composition for the treatment of chronic pharyngitis the most according to claim 4, it is characterised in that described pharmaceutically acceptable
Adjuvant includes but not limited to dextrin, lactose, starch, sucrose, glucose, microcrystalline Cellulose, magnesium stearate, manna
One or more of sugar, methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose, glycerol and steviosin.
7. the drug extract treating chronic pharyngitis, it is characterised in that it passes through for the pharmaceutical composition described in claim 1
Extraction solvent extracts and the extracting solution that obtains or extractum；Described Extraction solvent is selected from water or alcohol.
8. treat the preparation method of the pharmaceutical composition of chronic pharyngitis described in a claim 1, it is characterised in that by each crude drug
Respectively or extract together after mixing and obtain extract, after then mixing with adjuvant, make acceptable preparation agent on pharmaceutics
Type.
The preparation method of the pharmaceutical composition for the treatment of chronic pharyngitis the most according to claim 8, it is characterised in that it include as
Lower step:
(1) take the Radix Astragali, Fructus Ligustri Lucidi Preparata, the Rhizoma Atractylodis Macrocephalae, Poria, Radix Curcumae, Herba Euphorbiae Helioscopiae and Semen Oroxyli, boiling, merge decoction liquor,
Filtering, filtrate concentrates, and precipitate with ethanol, stands, receives cream, dry, pulverize into extract powder；
(2) take above-mentioned extract powder interpolation adjuvant and make acceptable preparation formulation on pharmaceutics.
10. the pharmaceutical composition of the treatment chronic pharyngitis described in claim 1 application in preparation treatment chronic pharyngitis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610286872.8A CN105853917B (en) | 2016-04-29 | 2016-04-29 | A kind of pharmaceutical composition and its preparation method and application for treating chronic pharyngitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610286872.8A CN105853917B (en) | 2016-04-29 | 2016-04-29 | A kind of pharmaceutical composition and its preparation method and application for treating chronic pharyngitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105853917A true CN105853917A (en) | 2016-08-17 |
| CN105853917B CN105853917B (en) | 2019-06-21 |
Family
ID=56628911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610286872.8A Active CN105853917B (en) | 2016-04-29 | 2016-04-29 | A kind of pharmaceutical composition and its preparation method and application for treating chronic pharyngitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105853917B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1513508A (en) * | 2003-06-03 | 2004-07-21 | 金陵药业股份有限公司技术中心 | Medicine composition for treating uppe respiration channel infetion and its preparing process |
| CN103933398A (en) * | 2014-04-22 | 2014-07-23 | 湖州康企药业有限公司 | Traditional Chinese medicine compositionfor treating chronic pharyngitis |
-
2016
- 2016-04-29 CN CN201610286872.8A patent/CN105853917B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1513508A (en) * | 2003-06-03 | 2004-07-21 | 金陵药业股份有限公司技术中心 | Medicine composition for treating uppe respiration channel infetion and its preparing process |
| CN103933398A (en) * | 2014-04-22 | 2014-07-23 | 湖州康企药业有限公司 | Traditional Chinese medicine compositionfor treating chronic pharyngitis |
Non-Patent Citations (3)
| Title |
|---|
| 国家药典委员会: "《国家药品标准新药转正标准第84册》", 31 August 2001 * |
| 范秀东: "慢性咽炎证治的现代文献研究", 《中国优秀硕士论文全文数据库医药卫生科技辑》 * |
| 陈国丰: "论慢喉痹", 《中华中医药学会耳鼻咽喉科分会第十二次学术研讨会暨嗓音言语听力医学专题学术研讨会论文集 》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105853917B (en) | 2019-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101167807B (en) | Traditional Chinese medicine preparation for treating chronic pharyngitis and its preparing process | |
| CN104435748A (en) | Dendrobium officinale compound preparation as well as preparation method and application of dendrobium officinale compound preparation | |
| CN103356891A (en) | Sugar-free throat-clearing lozenge and preparation method thereof | |
| CN101708279A (en) | Health-care tea for clearing away heat and moistening throat and preparation method thereof | |
| CN104383250A (en) | Pummelo peel dispersible tablets with function of relieving cough and preparation method thereof | |
| CN102885975A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN101380452A (en) | Preparation method of no-alcohol type Shexiang Qushu liquid oral preparation | |
| CN102579686B (en) | Traditional Chinese medicine lozenge and preparing method thereof | |
| CN105055841A (en) | Medicine for treating chronic pharyngitis and preparing method thereof | |
| CN103446445B (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency-type chronic bronchitis and preparation method thereof | |
| CN110755458A (en) | New use of penthorum chinense pursh for preventing and treating renal proteinuria | |
| CN103845633B (en) | It is a kind of to treat Chinese medicine composition of canker sore and preparation method thereof | |
| CN105853917A (en) | Pharmaceutical composition for treating chronic pharyngitis and preparation method and application thereof | |
| CN100430085C (en) | Medicine for ventilating the lung and resolving phlegm to relieve cough and preparing method | |
| CN1660260A (en) | Effervescence grains of reducing fever and relieving a cough for infant and preparation method | |
| CN102526488B (en) | Traditional Chinese medicine composition with pharynx-cleaning effect | |
| CN102755519B (en) | Kudzuvine root-kudzuvine flower anti-canker sore particle and preparation method thereof | |
| CN106310027A (en) | Compound dendrobium lung-clearing preparation, preparation method and application thereof | |
| CN103977127A (en) | Traditional Chinese medicine composition for treating infantile asthma and preparation method thereof | |
| CN104189833A (en) | Process for preparing xiaoyao pills | |
| CN113893276B (en) | Sleep improving composition, and preparation method and application thereof | |
| CN104147229B (en) | A kind of compound Chinese medicinal preparation for the treatment of female climacteric syndrome kidney yin and yang deficiency type | |
| CN103520475B (en) | A kind of pharmaceutical composition being used for the treatment of skin pruritus | |
| CN114848764B (en) | Traditional Chinese medicine compound composition for preventing and treating liver injury and preparation method and application thereof | |
| CN116350686B (en) | Medicinal and edible traditional Chinese medicine composition for treating dental ulcer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |